University of Oslo

Address Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership
University of Oslo and Oslo University Hospital
P.O. Box 1137 Blindern
NO-0318 Oslo
Norway
Platforms ATMP & Biological, Imaging & Tracing, Small Molecules, Vaccines

The University of Oslo is Norway’s oldest and highest rated institution of research and education with 28 000 students and 7000 employees. As a classical university with a broad range of academic disciplines, UiO has top research communities in most areas. Moreover, UiO has a strategic focus on interdisciplinary research in the fields of energy and life sciences in particular.

The Faculty of Medicine consists of 4 institutes: Institute of Clinical Medicine, Institute of Basic Medical Sciences, Institute of Health and Society and Centre for Molecular Medicine Norway.

Research areas are:

  • From «bench to bedside»
    – Basic, translational and clinical research within medicine and health sciences
  • Life sciences
  • Health management, economics and ethics
  • Community medicine and global health

17 national and regional core research infrastructures and facilities are jointly hosted and operated with Oslo University Hospital. Oslo also have partnerships with several European Research Infrastructures; EATRIS, EU Openscreen, BBMRI, ECRIN and Euro-Bioimaging.

Centre for Molecular Medicine Norway (NCMM, www.ncmm.uio.no) was established in 2008 as a partner institution of the European Molecular Biology Laboratory (www.embl.org) and together with nodes in Finland (FIMM), Sweden (MIMS) and Denmark (Dandrite) form the Nordic EMBL Partnership for Molecular Medicine. NCMM is a joint venture of the University of Oslo, Health Region South-East and the Research Council of Norway. The overall objective of NCMM is to conduct cutting-edge research in molecular medicine and facilitate translation of discoveries in basic medical research into clinical practice. NCMM focuses particularly on disease mechanisms where Norway has clear strengths, develops and adapts technologies for personalized medical applications and has unraveled new diagnostic methods and drug targets.

Contact

Facility https://www.med.uio.no/english/research/core-facilities/genomics-core-facility/
Head of the facility
  • Leonardo A. Meza-Zepeda

Expertise

Technologies
  • NGS-Whole genome sequencing (WGS)
  • NGS-Exome sequencing(WES)
  • ChIPSeq
  • Small RNA Seq
  • RNA Seq
  • Extended Cancer panel
  • Cancer panels & Liquid Biopsies

Contact

Facility https://www.med.uio.no/english/research/core-facilities/proteomics-core-facility/
Head of the facility
  • Tuula Anneli Nyman (Core facility leader)
  • Maria Stensland (Service leader)

Expertise

Technologies
  • MALDI-MS
  • SILAC/iTRAQ/TMT
  • FASP (Filter-Aided-Sample-Prep) digestion
  • QExactive or QExactive HF LC-MS/MS analysis
  • QExactive HF, Evosep-LC MS/MS analysis
Purposes
  • Research
  • Clinical use
  • Service

Share

Like what you read? Share your thoughts!